| abstract |
Disclosed are melanocortin receptor binding conjugates and methods of making and using the foregoing. The melanocortin receptor binding conjugates may comprise an alpha -MSH derivative-Fc immunoglobulin, optionally in combination with a pharmaceutically acceptable carrier. Further disclosed is a method of modulating a biological activity of a melanocortin receptor, comprising contacting the alpha -MSH derivative pharmaceutical composition with the melanocortin receptor. Another aspect disclosed is a method of modulating the melanocortin receptor-mediated condition, comprising administering the pharmaceutical composition of the invention to a patient in need thereof. |